drugset
drugset / Trial / NCT00179699

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

NCT00179699 ↗

Phase 1 Terminated 40 enrolled Celgene Corporation Prologue Research International · collab
Non-randomizedFactorialOpen-labelTreatment

Summary

Study will deteremine the MTD and evaluate the safety profile of oral lenalidomide on days 1-14 when combined with pemetrexed on day 1 of a 21 days cycle. Subjects will continue on study until documention of disease progression.

Timeline

Start
2005-09
Primary completion
—
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified — Oral
Background Pemetrexed Small molecule — —

Indications

non-small cell lung carcinoma